The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called ...

The FINANCIAL — Novartis announced on August 24 that the US Food and Drug Administration (FDA) has approved an expanded use for Promacta (eltrombopag) to include children 1 year of age and older with ...

Sept. 27, 2004 — Successful eradication of Helicobacter pylori infection results in significant platelet recovery in 56% of patients with chronic idiopathic thrombocytopenic purpura (ITP), according ...

Findings showed 23% of patients treated with rilzabrutinib achieved durable platelet response compared with none of the patients receiving placebo. The Food and Drug Administration (FDA) has approved ...

EAST HANOVER, N.J., Oct. 18, 2017 /PRNewswire/ -- Novartis today announced long-term study results supporting the positive safety and efficacy of Promacta (eltrombopag) in adults with ...

Purpose: The pharmacology, pharmacokinetics, dosage and administration, efficacy, safety, effects on quality of life, and place in therapy of romiplostim are reviewed. Summary: Romiplostim is a second ...

The phase 3 ADVANCE trial evaluated the efficacy and safety of efgartigimod in 131 adults with primary ITP. A clinically meaningful improvement in platelet count was observed in a significantly higher ...